Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- Registration Number
- NCT00409201
- Lead Sponsor
- Abarbanel Mental Health Center
- Brief Summary
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.
- Detailed Description
all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as well as blood tests, ecg and weight. they will then be tested using a computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given either a two week dose of placebo or treatment (2 mg \* 2 daily for first week, then 4 mg. day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. \* 2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is concluded at 6 weeks, following a readministration of tests. physical examination is also administered at the conclusion.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
- schizophrenia all types
- 18>
- uti
- >65
- non organic state
- no depression treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test
- Secondary Outcome Measures
Name Time Method esrs, progesterom, sexual functioning, covy, cgi, cgi improved
Trial Locations
- Locations (1)
Abarbanel Medical Mental Health Center
🇮🇱Bat Yam, Israel